The antibody drug improved muscle strength and function in adults with inflammatory muscle disease, setting up a potential label expansion for a therapy already generating billions.
A 12-week randomized study in adults with overweight found three daily servings of full-fat dairy didn’t harm cholesterol or body composition — but it was short and industry-funded.
LTG-001, an oral Nav1.8 blocker, eased post-surgical pain and cut opioid rescue use in a 343-patient trial published in the New England Journal of Medicine.
Retatrutide isn’t approved anywhere — but a gray market of compounders and ‘peptide’ sellers is already hawking copies, prompting Lilly to go to court.
CEO Mike Doustdar says the obesity giant will stick to smaller ‘bolt-on’ deals after clinical setbacks and a Wegovy sales miss, amid intensifying pressure from Eli Lilly.
The oral immunology drug ritlecitinib hit its co-primary endpoints in the TRANQUILLO studies, setting up filings for nonsegmental vitiligo, a condition with no approved oral therapy.
The startup’s AI runs virtual versions of trials to predict patient responses and flag design flaws — aiming at the industry’s roughly 90% clinical-trial failure rate.
Despite Phase 3 efficacy, Sanofi says its OX40 drug wouldn't meaningfully beat standard care — the latest setback for a once-promising class of immune drugs.
A French randomized trial found healthy, low-risk people over 75 who stopped their preventive statins were no worse off on death or heart events over three years — with big caveats.
Newly disclosed documents show Vertex was the only bidder left standing after a months-long courtship of the acromegaly drugmaker.
The Venrock-led round backs a platform that lets self-funded employers contract, in one deal, with thousands of advanced primary-care practices that sit outside insurance networks.
Co-founded by Georg Schett — who showed CAR-T can drive lupus into remission — the Deerfield-backed startup aims to reset the immune system with more convenient antibodies.